Pharmaceutical Safety Review • Low Interaction Classification

Clinical Review Prescription Drug Interactions & CYP450 Profile

Systematic analysis of cytochrome P450 enzyme metabolism, renal clearance competition, and clinical contraindications.

Absolute Clinical Contraindications

  • Severe pre-existing renal disease (eGFR < 30) requiring fluid restriction

Reported Clinical Adverse Events

  • Intracellular water retention (1.0 - 2.0 kg)
  • Mild GI distress if consumed with insufficient water

Hepatic Cytochrome P450 (CYP) & Transporter Pathways

Compounds that modulate CYP3A4, CYP2D6, or P-glycoprotein (P-gp) can alter the bioavailability of concurrent medications including statins, anticoagulants, immunosuppressants, and blood pressure therapies:

  • CYP3A4 Substrate / Inhibitor: Potential competition with oral medications metabolized through hepatic CYP3A4 pathways.
  • Gastrointestinal Transit Modulation: GLP-1 receptor agonists and delayed-release botanicals slow gastric emptying, which may delay Tmax for orally administered therapeutics.
  • Pharmacokinetic Half-Life Clearance: Systemic clearance requires approximately 5 elimination half-lives (Intramuscular saturation washout: 4 – 6 weeks).

Protocol Audit Links for Clinical Review

← Return to Clinical Review Monograph Calculate Weight Dosage Table → Launch Full Multi-Drug Interaction Checker →